• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Obamacare Is Killing Traditional Employer-Sponsored Health Insurance

Article

Obamacare is going to kill traditional employer-provided insurance. And that's probably a good thing.

Obamacare is going to kill traditional employer-provided insurance. And that’s probably a good thing. IBM, Time Warner, and now Walgreens have made headlines over the past two weeks by announcing that they plan to move retirees (IBM, Time Warner) and current employees (Walgreens) into private health insurance exchanges with defined contributions from employers.

Retiree health benefits—like lifetime pensions—have been shrinking in the private sector for decades (only about half of large employers still offer them, down from 80 percent 20 years ago), so it’s no surprise that the relatively few companies like IBM that do offer generous post-retirement health benefits are trying to find ways to keep them affordable.

Private Medicare exchanges are relatively well established at this point, so what is surprising is how quickly private insurance exchanges for current employees are attracting interest from employers. A recent survey by Accenture suggests that while Obamacare’s publicly funded exchanges will enroll more people at first, by 2018 more people will be enrolled in private exchanges (40 million) than the public exchanges (31 million). Accenture also reports that more than 1 in 4 employers are considering moving their employees to a private exchange format over the next 3 to 5 years.

Read the full story here: http://onforb.es/19vFngA

Source: Forbes

Related Videos
Eric Levin, Scripta
Margaret Krackeler, MD
Margaret Krackeler, MD
Margaret Krackeler, MD
A new study finds law enforcement presence in emergency departments may disrupt care. Lead author Prashasti Bhatnagar discusses policy and training solutions.
Jennifer Snow, MPA, NAMI
Jennifer Snow, MPA, NAMI
Aleata Postell, SVP of pharmacy business development, CenterWell Pharmacy
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Related Content
© 2026 MJH Life Sciences
AJMC®
All rights reserved.